Treatment modalities include liver transplantation for transthyretin-related (ATTR) amyloidosis, elimination of inflammation in amyloid A (AA) amyloidosis and intensive chemotherapy in ...

The FDA approved vutrisiran for the treatment of transthyretin amyloidosis ... form the amyloid protein, which is associated with CV damage and premature mortality in patients with ATTR-CM.

PET/CT, the first pan-amyloid diagnostic imaging agent, demonstrated 100% sensitivity and specificity for the diagnosis ...

Hereditary ATTR (ATTRv) amyloidosis occurs when a person is born with mutations in the TTR gene, which causes the liver to produce structurally abnormal transthyretin (TTR) protein with a propensity ...

Vutrisiran improved mortality and recurrent CV risks independent of disease severity and improved several other endpoints for ...

Transthyretin Amyloidosis Treatment Market explores key drug advances, regulatory developments, and growth trends through 2035 ...

which results from ATTR amyloidosis. Vutrisiran had already, in 2022, received FDA approval for the treatment of hereditary transthyretin amyloid polyneuropathy (hATTR-PN). The agency’s decision to ...

Alnylam Pharmaceutical’s has secured US Food and Drug Administration (FDA) approval for Amvuttra (vutrisiran), expanding its use to treat transthyretin amyloid cardiomyopathy (ATTR-CM), a rare ...

Transthyretin amyloidosis (ATTR) is a condition in which the body deposits a specific protein called amyloid into the heart, nerves, and other organs. It can lead to a heart disease called ...

124 I-evuzamitide (AT-01) PET/CT, the first pan-amyloid diagnostic imaging agent, demonstrated 100% sensitivity and specificity for the diagnosis of cardiac amyloidosis in patients suspected or ...